Security
Cardiol Therapeutics Inc. · CRDL
CRDLTSXCommon stockCurrentCIK 1702123Updated Nov 5, 2026
CRDL price & chart
Loading TradingView…
TSX:CRDL on TradingView ↗About the company
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular innate immune system response known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · CADSource
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossCAD | -33,818,874Source | -36,677,299Source | -28,128,292Source | -30,930,647Source |
| Additional Financial Items | ||||
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableCAD | 44,639Source | 42,379Source | 67,178Source | -144,184Source |
| AdjustmentsForSharebasedPaymentsCAD | 10,700,913Source | 14,277,406Source | 4,156,762Source | 5,013,185Source |
| GeneralAndAdministrativeExpenseCAD | 20,297,835Source | 26,264,521Source | 15,561,217Source | 22,373,798Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesCAD | 55,376Source | 41,532Source | 55,376Source | 53,934Source |
| ProceedsFromIssuingSharesCAD | 16,037,974Source | 21,355,588Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Additional Financial Items | ||||
| ApplicableTaxRatenumber | 0.27Source | 0.27Source | 0.27Source | 0.27Source |
| BasicEarningsLossPerShareCAD/shares | -0.39Source | -0.51Source | -0.44Source | -0.49Source |
| DilutedEarningsLossPerShareCAD/shares | -0.39Source | -0.51Source | -0.44Source | -0.49Source |
| GeneralAndAdministrativeExpenseCAD | 20,297,835Source | 26,264,521Source | 15,561,217Source | 22,373,798Source |
| ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillCAD | — | — | 0Source | — |
| IncomeTaxExpenseContinuingOperationsCAD | — | — | — | 0Source |
| OtherIncomeCAD | — | 28,223Source | 149,739Source | 164,443Source |
| ProfitLossFromOperatingActivitiesCAD | -34,316,296Source | -40,276,651Source | -29,785,504Source | -41,335,878Source |
| ResearchAndDevelopmentExpenseCAD | 14,018,461Source | 14,012,130Source | 14,224,287Source | 18,962,080Source |
| RevenueFromInterestCAD | 726,401Source | 1,193,342Source | 2,038,465Source | 1,237,632Source |
Filing attachments
tm2628681d1_ex99-1.htm · 6-K · 2026-11-03
Exhibit 99.1 CARDIOL THERAPEUTICS INC. US$75,000,000 OPEN MARKET SALE AGREEMENT SM November 3, 2026 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Cardiol Therapeutics Inc., a corporation organized under the laws of the Province of Ontario, Canada (the “Company”), confirms its agreement (this “Agreement”) with Jefferies LLC (the “Agent”) to issue and sell common shares of the Company (the “Common Shares”) having an aggregate offering price of up to US$75…
Read attachment ↗tm2628681d1_ex99-2.htm · 6-K · 2026-11-03
Exhibit 99.2 Borden Ladner Gervais LLP Bay Adelaide Centre, East Tower 22 Adelaide Street West Toronto, ON, Canada M5H 4E3 T 416.367.6000 F 416.367.6749 blg.com November 3, 2026 Consent of Borden Ladner Gervais LLP We hereby consent to the reference to our name under the headings “Documents Filed as Part of the U.S. Registration Statement” and “Legal Matters,” and to the reference to our name and use of our opinions under the headings “Eligibility for Investment” an…
Read attachment ↗ex991.htm · 6-K · 2026-09-23
EXHIBIT 99.1 Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy Original 110-patient enrollment target achieved ahead of the Company's end-of-September guidance. The MAVERIC Steering Committee recommends expanding enrollment to up to 150 patients to capture sufficient events for a robust assessment of CardiolRx™'s potential to reduce recurrence risk. The recommendation follows a blinde…
Read attachment ↗ex991.htm · 6-K · 2026-09-16
EXHIBIT 99.1 Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds Proceeds strengthen balance sheet ahead of pivotal Phase III MAVERIC trial data readout in recurrent pericarditis and extends cash runway into H1 2028. TORONTO, Sept. 16, 2026 /CNW/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce…
Read attachment ↗tm2625415d1_ex99-1.htm · 6-K · 2026-09-15
Exhibit 99.1 - 1 - CARDIOL THERAPEUTICS INC. (THE “CORPORATION”) CODE OF CONDUCT AND ETHICS The Corporation is committed to a culture of honesty, integrity and accountability and strives to operate its business in accordance with the highest ethical standards and applicable laws, rules and regulations. This Code of Business Conduct and Ethics (this “Code”) outlines the principles that should guide all directors, officers and employees of the Corporation in the performance of their duties. F…
Read attachment ↗tm2625221d1_ex99-1.htm · 6-K · 2026-09-11
Exhibit 99.1 Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns. Redacted information is indicated by: [***] EXCLUSIVE MASTER SERVICES AGREEMENT This MASTER SERVICES AGREEMENT (the “Agreement”) is entered into on April 17, 2018 and is effective as of June 12th, 2017 (the “Effective Date”) By and between, Dalton Chemical Laboratories, Inc. o/a Dalton Pharma Services, a corporation incorporated under …
Read attachment ↗